VSV-02

AXP000133.1 · Oncolytic virus

Platform
vesicular stomatitis virus (attenuated, bispecific antibody-armed)
Originator
Shanghai Rongrui Pharmaceutical Technology
Sponsor
Shanghai Rongrui Pharmaceutical Technology

Names

NameTypeSource
VSV-02preferred name, codecurator, ctgov
VSV-02 Injectionsynonymctgov

Virus

Role
Oncolytic
Family
Rhabdoviridae
Virus
vesicular stomatitis Indiana virus (NCBI Taxonomy 11277)
Strain
attenuated
Replication
replicating
Modifications
attenuated VSV encoding a CD3/PD-L1 bispecific antibody
Transgenes
CD3/PD-L1 bispecific antibody
Route
intravenous, intratumoral
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07260591VSV-02 Compassionate Use in Advanced Solid TumorsRecruitingPhase 12025-09-222026-09-306Advanced Solid Tumor; Breast Cancer; Cancer Treatment; Immunotherapy; Lung Cancer; Melanoma

Recent changes

No changes recorded in its trials yet.

Notes

Attenuated VSV engineered to encode a CD3/PD-L1 bispecific antibody, per the NCT07260591 registration. Compassionate-use/phase 1 study at the First Affiliated Hospital of Xinxiang Medical College, recruiting from December 2025; concurrent intravenous and intratumoral dosing. Attenuating mutations not described.

How to cite

VSV-02 (AXP000133.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000133.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.